- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Invented name:||Purevax RC|
|Auth. number :||EU/2/04/051|
|INN :||Not available|
|ATC:||Anatomical main group: QI - Immunologicals|
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AX - Other immunologicals
Chemical substance: QI06AX - Other immunologicals
(See WHO ATCvet Index)
|Indication:||Active immunisation of cats aged 8 weeks and older:|
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs and excretion.
Onsets of immunity have been demonstrated 1week after primary vaccination course for rhinotracheitis and calicivirus components.
The duration of immunity is 1 year after the last (re-)vaccination.
|Marketing Authorisation Holder:||Merial
29 avenue Tony Garnier, F-69007 Lyon, France
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which continues to be available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|25/02/2005||Centralised - Authorisation||EMEA/V/C/91||(2005)474 of 23/02/2005|
|18/07/2005||Centralised - Variation||EMEA/V/C/91/II/1|
|25/01/2008||Centralised - Variation||EMEA/V/C/91/II/2, 3, 4||(2008)332 of 22/01/2008|
|22/09/2008||Centralised - Variation||EMEA/V/C/91/II/5|
|20/02/2009||Centralised - Variation||EMEA/V/C/91/II/6||(2009)1182 of 17/02/2009|
|24/04/2009||Corrigendum||(2009)3096 of 21/04/2009|
|19/01/2010||Centralised - Renewal||EMEA/V/C/91/R/7||(2010)189 of 15/01/2010|
|30/01/2013||Centralised - Variation||EMEA/V/C/91/WS/325/G||(2013)526 of 28/01/2013|